- Catalent, Inc. Investor Warning: 4/25/2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
- CATALENT, INC. INVESTORS: April 25, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
- Catalent, Inc. to Present at March Investor Conferences
- Catalent Appoints Sridhar Krishnan to Lead New Global Operational Excellence Strategy, “The Catalent Way”
- Catalent Publishes Fourth Annual Corporate Responsibility Report Highlighting Achievements While Providing New Record Number of Patient Treatments
- Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary
- Catalent, Inc. Reports Second Quarter Fiscal 2023 Results
- Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast
- Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
- Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Catalent Inc (0C8:STU) closed at 60.28, 52.96% above the 52 week low of 39.41 set on Nov 28, 2022.
39.41Nov 28 2022112.06Jul 29 2022
Short selling activityProvided by S&P Global Market Intelligence
|Market cap||11.83bn USD|
|EPS (TTM)||2.26 |
Data delayed at least 15 minutes, as of Mar 31 2023.